Open-Label FURI Study, Showing Oral Ibrexafungerp’s Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
Analysis of first 20 patients confirms clinical antifungal activity of oral ibrexafungerp in patients with difficult-to-treat mucocutaneous and invasive fungal infections.
Source: Scinexis
Healthy Patients